VENITI is dedicated to advancing the treatment of venous disease through clinical research and innovative technology and solutions. Partnering with leading physicians, VENITI has developed the VICI Venous Stent specifically for the challenges of treating iliofemoral venous outflow obstruction.
Boston Scientific Corporation (NYSE: BSX) today announced it has signed an agreement to acquire VENITI, Inc., a privately-held company in Fremont, California which has developed and commercialized the VICI Venous Stent® System for treating venous obstructive disease. Boston Scientific has been an investor in VENITI since 2016.
We are excited to see that more patients who suffer from venous obstructive disease will get access to the VICI VENOUS STENT® System under the leadership of Boston Scientific. We are equally thrilled to be providing a great return for our early-stage investors, such as Prolog Ventures, who have supported us from the beginning.
- Catherine Matthes / CFO, VENITI